A neuroscience round this week was co-led by a hedge fund, not a healthcare VC. Better, worse, or just different capital for a company like that?

Options

• Better — faster decisions, deeper pockets
• Worse — less patient, less domain expertise when it matters
• Just different — good for the raise, risky for governance later
• Depends entirely on the term sheet, not who signed it